Status:
TERMINATED
Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Preeclampsia
Eligibility:
FEMALE
18-45 years
Phase:
PHASE2
Brief Summary
Introduction Preeclampsia is a multifactorial disease that is responsible of important adverse maternal and perinatal outcomes. Recently, it has been suggested that soluble fms-like tyrosine kinase 1,...
Detailed Description
Introduction Preeclampsia is a multifactorial disease that is responsible of important adverse maternal and perinatal outcomes. Recently, it has been suggested that soluble fms-like tyrosine kinase 1,...
Eligibility Criteria
Inclusion
- Severe preeclampsia at less than 26 weeks' gestation
- Singleton pregnancy
- Signed consent
Exclusion
- Multiple pregnancy
- Gestational age at 26 or above weeks' gestation
- Estimated foetal weight at diagnosis \<5th percentile
- Abnormal fetal heart rate at entry, where feasible (\>24 weeks' gestation)
- Maternal complications at diagnosis: Uncontrolled blood pressure, HELLP syndrome, abruption, eclampsia pulmonary edema, renal failure, liver hematoma
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02286284
Start Date
March 1 2015
End Date
November 1 2015
Last Update
December 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHIC
Créteil, France